(ALAMA) AMA - Ratings and Ratios

Exchange: PA • Country: France • Currency: EUR • Type: Common Stock • ISIN: GB00BNKGZC51

ALAMA: Remote, Assistance, Augmented, Reality,

AMA Corporation Plc (PA:ALAMA) specializes in the development and deployment of advanced remote assistance and video conferencing solutions, operating across 11 countries, including France, the United States, Romania, Germany, the United Kingdom, Hong Kong, China, Canada, Japan, Italy, and Spain. The companys flagship product, the XpertEye suite, integrates augmented reality (AR) technology, dynamic workflow management, and real-time scheduling capabilities, enabling seamless remote collaboration and expertise sharing. Its solutions are compatible with a wide range of devices, including smartphones, smart glasses, tablets, and specialized medical equipment such as microscopes, cameras, endoscopes, and dermatoscopes. The product lineup includes XE aR, XE aR+, XpertEye Proceed, and XpertEye Schedule, all designed to enhance operational efficiency in industries like healthcare, manufacturing, and education. AMA Corporation also offers complementary services such as project management, training, maintenance, technical support, and intellectual property rights management. Founded in 2004 and headquartered in Rennes, France, the company operates as a subsidiary of Guillemot Brothers S.A. and is listed on the Euronext Paris exchange under the ticker symbol ALAMA.

AMA Corporations solutions are particularly valued in the healthcare sector, where its AR-enabled tools facilitate remote medical consultations and training. The integration of XpertEye with medical devices such as endoscopes and dermatoscopes allows healthcare professionals to share high-resolution visuals in real time, improving diagnostic accuracy and enabling remote expert consultations. This has been especially critical in regions with limited access to specialized medical expertise. The companys global reach and cross-industry applicability position it as a key player in the growing remote collaboration and telemedicine markets.

Based on and , here is the 3-month forecast: The stock is expected to remain volatile with an ATR of 0.03, indicating moderate price swings. The SMA 20 (0.22) and SMA 50 (0.19) suggest downward momentum, while the SMA 200 (0.19) reflects a stable long-term trend. With a P/S ratio of 4.70, the stock is trading at a premium relative to its revenue, which may indicate elevated expectations. The P/B ratio of 1.87 suggests that the market values the companys assets higher than their book value. The lack of P/E data indicates either no earnings or significant losses, which could impact investor sentiment. Overall, the stock is likely to face headwinds in the near term but may stabilize as the market reassesses its fundamentals.

Additional Sources for ALAMA Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ALAMA Stock Overview

Market Cap in USD 16m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Technology
IPO / Inception

ALAMA Stock Ratings

Growth 5y -71.7%
Fundamental -25.3%
Dividend 0.0%
Rel. Strength Industry 11.7
Analysts -
Fair Price Momentum 0.18 EUR
Fair Price DCF -

ALAMA Dividends

No Dividends Paid

ALAMA Growth Ratios

Growth Correlation 3m 82%
Growth Correlation 12m -29.1%
Growth Correlation 5y -91.7%
CAGR 5y -57.94%
CAGR/Max DD 5y -0.59
Sharpe Ratio 12m -0.03
Alpha 16.72
Beta 0.77
Volatility 157.76%
Current Volume 55.9k
Average Volume 20d 53.6k
What is the price of ALAMA stocks?
As of March 16, 2025, the stock is trading at EUR 0.25 with a total of 55,903 shares traded.
Over the past week, the price has changed by -9.49%, over one month by +13.24%, over three months by +64.24% and over the past year by +12.73%.
Is AMA a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, AMA (PA:ALAMA) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -25.34 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALAMA as of March 2025 is 0.18. This means that ALAMA is currently overvalued and has a potential downside of -28%.
Is ALAMA a buy, sell or hold?
AMA has no consensus analysts rating.
What are the forecast for ALAMA stock price target?
According to ValueRays Forecast Model, ALAMA AMA will be worth about 0.2 in March 2026. The stock is currently trading at 0.25. This means that the stock has a potential downside of -20%.
Issuer Forecast Upside
Wallstreet Target Price 0.1 -60%
Analysts Target Price - -
ValueRay Target Price 0.2 -20%